Drugs / NK-104-CR
last change Nov 2017 re-read 2 minutes ago

NK-104-CR

Developed for
hyperlipidemia
Investigated by
Kowa Research Institute, Inc.

Trials 2 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02799758 Feb 2016 → Jul 2017 hyperlipidemia Kowa Research Institute, Inc. Withdrawn No outcome recorded
Phase 3 NCT02670434 Jan 2016 → Jul 2017 hyperlipidemia Kowa Research Institute, Inc. Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NK-104-CR ClinicalTrials.gov intervention name — accepted as the source's own label NCT02670434
1

NCT02799758

Route Oral orally once daily” NCT02799758